

Strides Pharma Global Pte. Limited
Balance Sheet as at March 31, 2025

		Amount in USD	
	Note No.	31-Mar-25	31-Mar-24
A ASSETS			
I Non-current assets			
(a) Property, plant and equipment		131,630	101,983
(b) Right of use assets		-	100,629
(c) Other intangible assets		51,285,099	58,840,796
(d) Intangibles assets under development		5,897,746	-
(e) Financial assets			
(i) Investments	1	75,415,415	65,695,833
(ii) Loans	2	-	71,570,510
(iii) Other financial assets	3	17,468	5,896,568
Total non-current assets		132,747,358	202,206,319
II Current assets			
(a) Inventories		5,931,302	7,443,618
(b) Financial assets			
(i) Investments	4	-	12,685,367
(ii) Trade receivables	5	146,997,016	159,876,096
(iii) Cash and cash equivalents	6	2,643,035	3,495,581
(iv) Loans	7	48,693,052	544,483
(c) Other Current Assets	8	6,135,848	2,321,965
Total current assets		210,400,253	186,367,110
TOTAL ASSETS		343,147,611	388,573,429
B EQUITY AND LIABILITIES			
I Equity			
(a) Equity share capital	9	196,476,219	178,616,656
(b) Reserves and Surplus	10	(26,291,518)	(26,684,641)
Total Equity		170,184,700	151,932,015
II Liabilities			
1 Non-current liabilities			
(a) Financial liabilities			
(i) Lease liability		-	56,911
(b) Deferred tax liabilities (net)		6,496,008	5,727,069
Total non-current liabilities		6,496,008	5,783,980
2 Current liabilities			
(a) Financial liabilities			
(i) Borrowings	11	12,500,000	18,500,000
(ii) Trade payables	12	148,909,505	208,588,419
(iii) Lease liability		52,026	52,900
(iv) Other financial liabilities	13	218,987	243,056
(b) Provisions	14	2,580,258	1,521,073
(c) Other current liabilities	15	44,774	17,846
(d) Current income tax liabilities	16	2,161,353	1,934,140
Total current liabilities		166,466,903	230,857,434
TOTAL EQUITY AND LIABILITIES		343,147,611	388,573,429

Strides Pharma Global Pte. Limited
Statement of Profit And Loss for the year ended March 31, 2025

Particulars	Note No.	Amount in USD	
		31-Mar-25	31-Mar-24
1 Revenue from operations	17	233,709,814	241,391,681
2 Other Income	18	7,092,515	5,595,541
3 Total Revenue (1+2)		240,802,329	246,987,222
4 Expenses			
(a) Cost of goods sold		177,853,145	173,515,630
(b) Employee benefits expense	19	1,569,764	1,840,604
(c) Finance costs	20	2,013,365	6,615,953
(d) Depreciation and amortisation expense		7,093,565	8,024,151
(e) Other expenses	21	31,648,648	28,070,816
Total expenses		220,178,488	218,067,154
5 Profit / (Loss) before exceptional items and taxes (3-4)		20,623,842	28,920,068
6 Exceptional Item		(388,377)	(4,041,006)
7 Profit / (Loss) before taxes (5+6)		21,012,219	24,879,062
8 Tax Expense:			
(1) Current tax		1,991,736	1,764,523
(2) Deferred tax		768,939	5,027,834
(3) Prior year taxes		(1,141)	-
Total tax expenses		2,759,534	6,792,357
9 Profit / (Loss) for the year after tax		18,252,685	18,086,705

Strides Pharma Global Pte. Limited
Notes forming part of financial statement

Note No.

1	Non current investments	Amount in USD	
	Particulars	31-Mar-25	31-Mar-24
	Investment in subsidiaries and associates	67,282,974	65,695,833
	Investment in Mutual funds	8,132,440	-
	Total	75,415,415	65,695,833
2	Non-current loans	Amount in USD	
	Particulars	31-Mar-25	31-Mar-24
	Loans to related parties	-	71,570,510
	Total	-	71,570,510
3	Non-current financial asset	Amount in USD	
	Particulars	31-Mar-25	31-Mar-24
	Unsecured, considered good:		
	Other Receivables - Non Current	17,468	5,896,568
	Total	17,468	5,896,568
4	Current Investments	Amount in USD	
	Particulars	31-Mar-25	31-Mar-24
	Other investments (Carried at fair value through profit or loss)	-	12,685,367
	Total	-	12,685,367
5	Trade Receivables	Amount in USD	
	Particulars	31-Mar-25	31-Mar-24
	Unsecured		
	Trade Receivables	21,909,103	31,961,912
	Receivable from related parties	125,087,913	127,914,184
	Total	146,997,016	159,876,096
6	Cash & Cash Equivalents	Amount in USD	
	Particulars	31-Mar-25	31-Mar-24
	Cash in hand	1,318,132	4,908
	Balances with banks:	-	-
	In current accounts	1,051,816	3,225,187
	In deposit accounts	273,087	265,486
	Total	2,643,035	3,495,581
7	Loans	Amount in USD	
	Particulars	31-Mar-25	31-Mar-24
	Loans to related parties	48,693,052	544,483
	Total	48,693,052	544,483
8	Other current assets	Amount in USD	
	Particulars	31-Mar-25	31-Mar-24
	Prepaid expenses	468,519	577,819
	Other Receivables	5,667,329	1,744,146
	Total	6,135,848	2,321,965
9	Share capital	Amount in USD	
	Particulars	31-Mar-25	31-Mar-24
	Issued, subscribed and fully paid-up		
	Equity share capital	18,254,063	394,500
	Preference share capital	178,222,156	178,222,156
	Total	196,476,219	178,616,656

Strides Pharma Global Pte. Limited
Notes forming part of financial statement

Note No.

10 Reserves and surplus		Amount in USD	
Particulars	31-Mar-25	31-Mar-24	
Share Application money Pending Allotment	-	17,859,563	
Capital Reserve	1,184,141	1,184,141	
Surplus in statement of profit and loss			
Opening balance	(45,728,345)	(63,815,050)	
Add: Profit / (Loss) for the year	18,252,685	18,086,705	
Closing balance	(27,475,660)	(45,728,345)	
Total	(26,291,518)	(26,684,641)	

11 Current borrowings		Amount in USD	
Particulars	31-Mar-25	31-Mar-24	
Unsecured			
Loan from Banks	12,500,000	18,500,000	
Total	12,500,000	18,500,000	

12 Trade payables		Amount in USD	
Particulars	31-Mar-25	31-Mar-24	
Trade Payables	148,909,505	1,182,605	
Payable to related parties	-	207,405,814	
Total	148,909,505	208,588,419	

13 Other Current financial Liabilities		Amount in USD	
Particulars	31-Mar-25	31-Mar-24	
Interest accrued but not due	167,597	145,276	
Other payables:			
- Statutory remittances	-	35,465	
Other Payables	51,390	62,315	
Total	218,987	243,056	

14 Provisions		Amount in USD	
Particulars	31-Mar-25	31-Mar-24	
Provision for expenses	2,580,258	1,521,073	
Total	2,580,258	1,521,073	

15 Other current liabilities		Amount in USD	
Particulars	31-Mar-25	31-Mar-24	
Advance received from customer	44,774	17,846	
Total	44,774	17,846	

16 Current Income tax liability		Amount in USD	
Particulars	31-Mar-25	31-Mar-24	
Provision for taxation	2,161,353	1,934,140	
Total	2,161,353	1,934,140	

17 Revenue From Operation		Amount in USD	
Particulars	31-Mar-25	31-Mar-24	
Sales of Products	229,717,866	232,505,772	
Sales of Service	3,868,331	8,657,263	
Support Service Income	123,617	228,646	
Total	233,709,814	241,391,681	

Strides Pharma Global Pte. Limited
Notes forming part of financial statement

Note No.

18 Other income **Amount in USD**

Particulars	31-Mar-25	31-Mar-24
Dividend received	-	97,390
Interest Income	-	7,932
Bank Interest Income	9,453	145,680
Interest Income from Loan to Subsidiaries	-	4,848,545
Gain on sale of property, plant and equipment	-	6,376
Rental Income	-	338,181
Guarantee Commission Received	9,491	113,937
Gain on fair valuation of mutual funds	306,586	-
Forex Ex. Gain (Net)	171,645	-
Interest Income from Investment	6,595,340	-
Others - Income	-	37,500
Total	7,092,515	5,595,541

19 Employee Benefits Expense **Amount in USD**

Particulars	31-Mar-25	31-Mar-24
Staff Costs	1,539,659	1,784,003
Contribution to DCP	30,105	56,601
Total	1,569,764	1,840,604

20 Finance Cost **Amount in USD**

Particulars	31-Mar-25	31-Mar-24
Guarantee Commission	-	432,217
Amortization of Loan upfront Fee	540,096	-
Interest Expense on Bank Loans	1,375,528	5,070,015
Others - Finance cost	97,741	1,113,721
Total	2,013,365	6,615,953

21 Other Expenses **Amount in USD**

Particulars	31-Mar-25	31-Mar-24
Legal and professional	555,328	1,022,296
Selling and Distribution Expenses	-	528,060
Power, fuel and water charges	88,947	141,255
Consumables	175,518	394,729
Repair and maintenance-machinery	9,102	142,730
Repair and maintenance-others	13,472	114,925
Rent	51,388	50,572
Rates and taxes	867,295	476,660
Communication charges	18,431	25,765
Regulatory fees	-	1,235,554
Capacity reservation fee	24,990,438	21,000,000
Repair and maintenance-buildings	-	37,720
Travelling and conveyance	16,656	30,375
Insurance	81,724	109,182
Sales commission	27,710	106,347
Provision for bad debts	(6,283)	378,271
R&D Expenses	38,094	58,843
Forex Loss	-	256,870
Write down of assets	3,288,539	574,814
Audit fees	163,344	214,569
Support service fees	835,792	598,549
Donations	615	4,149
Printing and stationery	1,623	1,716
Royalty expenses	246,514	213,706
Loss on sale of assets	42,452	12,602
Demurage	125,952	-
Others	15,995	340,557
Total	31,648,648	28,070,816